T1	p 92 114	stable COPD patients .
T2	p 129 144	COPD patients ,
T3	p 594 669	, 60 COPD patients underwent dyspnea evaluation ( VAS score ) and pulmonary
T4	p 729 746	300?g indacaterol
T5	i 556 571	bronchodilators
T6	i 718 725	placebo
T7	i 735 746	indacaterol
T8	i 1352 1367	bronchodilators
T9	i 1370 1381	?sRAW-based
T10	o 20 48	acute bronchodilator effects
T11	o 70 80	resistance
T12	o 209 226	expiratory volume
T13	o 254 268	vital capacity
T14	o 292 328	peripheral airway smooth muscle tone
T15	o 363 385	dynamic hyperinflation
T16	o 388 423	gas trapping , and possibly dyspnea
T17	o 623 686	dyspnea evaluation ( VAS score ) and pulmonary function testing
T18	o 893 938	changes of intrathoracic gas volume ( ?ITGV )
T19	o 964 987	residual volume ( ?RV )
T20	o 1172 1220	?ITGV ( p=0.002 ) , ?RV ( p=0.023 ) , and ?VAS (
T21	o 1504 1530	lung mechanics and dyspnea